ArticleNew journal of chemistry = Nouveau journal de chimie2010
Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications.
Article in New journal of chemistry = Nouveau journal de chimie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- A systematic review on vaccine developmental approaches: Evaluating efficacy, and addressing challenges of infectious diseases in the post-COVID-19 era.Virus research · 2026Pooled it
- Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors.Molecular therapy. Nucleic acids · 2025Review
- Innovative design and comprehensive characterization of a valine-enhanced lipid nanoparticle-coated mRNA vaccine targeting the SARS-CoV-2 S-RBD antigen.Scientific reports · 2025Article
- mRNA medicine: Recent progresses in chemical modification, design, and engineering.Nano research · 2024Article
- Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5' cap-modified mRNAs.Nucleic acids research · 2023Article
- The potential of N2-modified cap analogues for precise genetic manipulation through mRNA engineering.Frontiers in molecular biosciences · 2023Article
- mRNA Vaccine Platform: mRNA Production and Delivery.Russian journal of bioorganic chemistry · 2023Article
- The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.Molecular therapy. Nucleic acids · 2022Review
- Synthetic modified messenger RNA for therapeutic applications.Acta biomaterialia · 2021Review
- Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2020Review
- Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.Methods (San Diego, Calif.) · 2018Article
- Modified ARCA analogs providing enhanced translational properties of capped mRNAs.Cell cycle (Georgetown, Tex.) · 2018Article
- Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.Nucleic acids research · 2016Article
- Biomaterials for mRNA delivery.Biomaterials science · 2015Article
- Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy.Expert opinion on biological therapy · 2015Review
- Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.Nucleic acids research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
We describe the chemical synthesis and preliminary biophysical and biochemical characterization of a series of mRNA 5' end (cap) analogs designed as reagents for obtaining mRNA molecules with augmented translation efficiency and stability in vivo and as useful tools to study mRNA metabolism. The analogs share three structural features: (i) 5',5'- bridge elongated to tetraphosphate to increase their affinity to translation initiation factor eIF4E (ii) a single phosphorothioate modification at either the α, β, γ or δ-position of the tetraphosphate to decrease their susceptibility to enzymatic degradation and/or to modulate their interaction with specific proteins and (iii) a 2'-O-methyl group in the ribose of 7-methylguanosine, characteristic to Anti-Reverse Cap Analogs (ARCAs), which are incorporated into mRNA during in vitro transcription exclusively in the correct orientation. The dinucleotides bearing modified tetraphosphate bridge were synthesized by ZnCl(2) mediated coupling between two mononucleotide subunits with isolated yields of 30-65%. The preliminary biochemical results show that mRNAs capped with new analogs are 2.5-4.5 more efficiently translated in a cell free system than m(7)GpppG-capped mRNAs, which makes them promising candidates for RNA-based therapeutic applications such as gene therapy and anti-cancer vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.